Stocks surrendered early gains to finish with losses today as lingering worries over global trade and lack of definitive domestic triggers held investors back.
The reshuffle of the S&P BSE Sensex composition effective from June 18 will hit sectors like healthcare, private banks, technology, consumer and auto, a report said.
Markets gave up early gains but managed to end higher for the third straight session today, driven by robust buying in technology and healthcare stocks amid positive macro data.
The BSE Sensex rose 47 points today to close at 35,739.16 in see-saw trade, led by gains in software exporters and healthcare stocks.
U.S. stocks edged higher on Friday as healthcare shares rose ahead of President Donald Trump’s speech on curbing prescription drug costs that is seen as largely sparing the industry.
Yet another M&A deal stole the spotlight in British stocks trading as a $3 billion bid sent Zoopla owner ZPG surging 30%, while the FTSE 100 steadied after a strong run.
Sensex tumbled over 188 points to close at 34,915.38, extending its slide for the second straight session due to selling in auto, healthcare, metal and FMCG stocks.
The Sensex jumped over 330 points, or 0.97 percent, to close at 34,413.16, while the NSE Nifty too recovered over 100 points, or 0.96 per cent, to end at 10,576.85.
Healthy buying activities in stocks of healthcare, banking and auto stocks pushed the key Indian equity indices higher on Thursday after seven consecutive days of losses.
Wall Street’s main indexes edged lower as declines in healthcare and energy stocks paused a rally that had driven the Dow to its fastest ever 1,000 point gain.
Mulls 1:1 Bonus Share Issue
CITY UNION BANK
To Issue 1:10 Bonus Shares; Record Date At July 11
Approved Bonus Issue Of 1:2; Record Date At June 27
Arm Buys Under-Construction Asset For Rs 234 Cr In Indore At Auction
Brownfield Acquisition To Add Approx. 1.1 Mn Sq. Ft. To Co's Retail Portfolio
Co In Pact To Buy 95% Of Climate Tech Pty, Australia
Deal Size Stands At Rs 201-211 Cr In Valuation
JLR Investor Presentation:
Have Exciting Products, Plans In The Pipeline To Generate Sustainable Growth
Aiming For A 4-7% EBIT Margin Over Medium Term, Will Invest 4.5 Bn GBP In FY19-21
Aiming For A 7-9% EBIT Margin Over Long Term
Long Term Investment Pegged At 12-13% Of Revenue
Retail Volume Grew By 1.7% & Revenue Grew By 6% In FY18
Also Launched Jaguar I-Pace As Co's First All Battery Electric Vehicle
To Set Up 5 Lk KL/Annum Plant At Visakhapatnam For Rs 1,785 Cr
To Set Up 6 Lk KL/Annum Plant In Mysore For Rs 2,300 Cr
Co's International Business Did Not Perform Well In FY18
Economy & Inflated Currency Hit Co's Egyptian Operations
To Launch Generic Tadalafil After Filing ANDA With USFDA
Sterile Drug Product Manufacturing Facility In Bengaluru Receives EIR From USFDA
USFDA's Pre-Approval & Inspection Of Facility Done In April & May 2018
EIR Notifies That The Inspection Stands Closed
Co Committed To Global Standards Of Quality & Compliance
Dr Reddy's Loses Patent Case With Eli Lilly Over Alimta
Co Cannot Launch Its Alternative Salt Forms Until The Eli Lilly Patent Expires
The U.S. District Court For The Southern District Of Indiana Ruled In Favour Of Lilly
The Eli Lilly Patent Expires In May 2022